Who are AR1001's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Brenzavvy, Jardiance, A5, Concomitant therapy 14 days, CTM Boost, Comparator monotherapy empagliflozin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ar1001.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

AR1001 — Competitive Intelligence Brief

AR1001 (AR1001) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SGLT2 inhibitor. Area: Diabetes.

phase 3 SGLT2 inhibitor SGLT2 Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

AR1001 (AR1001) — AriBio Co., Ltd.. AR1001 is a small molecule that targets the SGLT2 receptor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
AR1001 TARGET	AR1001	AriBio Co., Ltd.	phase 3	SGLT2 inhibitor	SGLT2
Brenzavvy	BEXAGLIFLOZIN	Theracosbio	marketed	Sodium-Glucose Cotransporter 2 Inhibitor [EPC]	SGLT2	2023-01-01
Jardiance	empagliflozin	Boehringer Ingelheim	marketed	Sodium-Glucose Cotransporter 2 Inhibitor [EPC]	SGLT2	2014-01-01
A5	A5	Breath of Life International Pharma Ltd	marketed	SGLT2 inhibitor	SGLT2
Concomitant therapy 14 days	Concomitant therapy 14 days	Incheon St.Mary's Hospital	marketed	SGLT2 inhibitor	SGLT2
CTM Boost	CTM Boost	Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)	marketed	SGLT2 inhibitor	SGLT2
Comparator monotherapy empagliflozin	Comparator monotherapy empagliflozin	The George Institute	marketed	SGLT2 inhibitor	SGLT2 (sodium-glucose cotransporter 2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (SGLT2 inhibitor class)

Daewon Pharmaceutical Co., Ltd. · 13 drugs in this class
Qilu Pharmaceutical Co., Ltd. · 10 drugs in this class
Takeda · 10 drugs in this class
Taejoon Pharmaceutical Co., Ltd. · 9 drugs in this class
Hanmi Pharmaceutical Company Limited · 9 drugs in this class
Addpharma Inc. · 9 drugs in this class
GlaxoSmithKline · 7 drugs in this class
AO GENERIUM · 7 drugs in this class
Merck Sharp & Dohme LLC · 7 drugs in this class
Nobelpharma · 6 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AR1001 — Competitive Intelligence Brief. https://druglandscape.com/ci/ar1001. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab